Rémy Duléry: T cell malignancies after CAR T cell therapy in the DESCAR-T registry

Rémy Duléry: T cell malignancies after CAR T cell therapy in the DESCAR-T registry

Rémy Duléry, Professor of Hematology at Sorbonne University, Saint-Antoine Hospital in Paris, shared on X:

“Happy to share our work published in Nature Medicine

We analyzed 3,066 patients from the French DESCAR-T registry who received CARTcell therapy. Our findings indicate a very low risk of T-cell malignancy after CAR T-cell therapy: only 1 case (0.03%).”

T cell malignancies after CAR T cell therapy in the DESCAR-T registry | Nature Medicine

Authors: Remy Dulery, Vincent Guiraud, Sylvain Choquet, Catherine Thieblemont, Emmanuel Bachy, Stéphane Barete, Ève Todesco, Bertrand Arnulf, Nicolas Boissel, André Baruchel, Jacques-Olivier Bay, Steven Le Gouill and Roch Houot.

Rémy Duléry: T cell malignancies after CAR T cell therapy in the DESCAR-T registry

 

André Baruchel Bertrand Arnulf cancer Catherine Thieblemont Emmanuel Bachy Ève Todesco Jacques-Olivier Bay Nicolas Boissel OncoDaily Oncology Rémy Duléry Stéphane Barete Steven Le Gouill and Roch Houot Sylvain Choquet Vincent Guiraud